Non-mRNA COVID vaccines use older, more established vaccine technologies to protect against COVID-19 without delivering genetic instructions to your cells. In the United States, the main non-mRNA option currently available is Novavax, a protein subunit vaccine approved for people ages 12 and older. Other non-mRNA types, including viral vector and inactivated virus vaccines, have been used widely in other countries.
How Protein Subunit Vaccines Work
The Novavax vaccine works differently from the Pfizer and Moderna shots. Instead of sending mRNA instructions into your cells to build spike proteins, it delivers pre-made spike proteins directly. These are lab-manufactured copies of the spike protein found on the surface of the COVID-19 virus, combined with an ingredient called an adjuvant that amplifies your immune response.
After the vaccine is injected into your upper arm, nearby cells encounter these foreign proteins and recognize them as something that doesn’t belong. The adjuvant kicks the immune system into higher gear, prompting it to produce antibodies and activate defensive white blood cells. Your body essentially learns to recognize and fight the spike protein without ever being exposed to the actual virus or to any genetic material.
This protein-based approach has decades of history behind it. Vaccines for hepatitis B and whooping cough use similar technology, which is one reason some people feel more comfortable with this option.
What the Adjuvant Does
Protein subunit vaccines need a boost that mRNA vaccines don’t. On their own, the spike proteins in Novavax wouldn’t trigger a strong enough immune response to be protective. That’s where Matrix-M comes in. This adjuvant is made from saponins extracted from the bark of the Chilean soap bark tree, combined with cholesterol and fatty molecules to form tiny cage-like nanoparticles.
Matrix-M does more than just amplify the immune response. It helps the body produce a balanced mix of immune cell types and antibody classes, which can broaden protection. Research published in Frontiers in Drug Delivery found that Matrix-M adjuvanted vaccines generated antibodies with cross-protective properties, meaning they may offer some defense even as the virus mutates. The adjuvant also helps reduce the amount of spike protein needed per dose, which can lower the chance of side effects from the protein itself.
Novavax Availability and Dosing
Novavax (brand name Nuvaxovid) is FDA-approved for people ages 12 and older. For the 2025-2026 season, it is administered as a single dose. Each shot contains 5 micrograms of spike protein and 50 micrograms of Matrix-M adjuvant. You don’t need to have received any previous COVID vaccines to get it, and you don’t need a multi-dose primary series.
One practical advantage: protein subunit vaccines are stored at standard refrigerator temperatures, between 2°C and 8°C (36°F to 46°F). Early mRNA vaccines required ultra-cold or frozen storage, which created distribution challenges. Novavax can sit in an ordinary pharmacy refrigerator alongside flu shots, though it must never be frozen since the aluminum-style adjuvant components lose potency at freezing temperatures.
How It Performs Against Current Variants
Novavax updates its vaccine formula to match circulating variants, just as the mRNA vaccines do. Data presented to the FDA’s advisory committee showed that a single Novavax booster matched to the JN.1 variant produced a roughly 4.5 to 5.5-fold increase in neutralizing antibodies across multiple virus strains, including newer sublineages. Pre-boost antibody levels of around 60 to 185 rose to 270 to 900 after vaccination, depending on the specific variant tested.
Mouse studies also showed strong cross-reactivity. Animals vaccinated with the JN.1 formula produced high antibody levels against several JN.1 sublineages, with titers ranging from about 2,600 to 5,900. Novavax has described the vaccine’s overall profile as showing “favorable reactogenicity and excellent efficacy” in large, diverse populations, though specific percentage efficacy figures for the latest formula against the newest variants haven’t been published yet.
Who Might Prefer a Non-mRNA Vaccine
The most clear-cut medical reason to choose Novavax is an allergy to an ingredient in the mRNA vaccines. Both Pfizer and Moderna contain polyethylene glycol (PEG), a compound that causes allergic reactions in a small number of people. Novavax does not contain PEG. The CDC explicitly states that people with a contraindication to one COVID vaccine type can receive the other type in a standard vaccination setting, no special observation period or allergy clinic required.
Beyond allergies, some people simply prefer the protein subunit approach because it uses a more familiar technology. No genetic material enters your cells. The vaccine delivers a finished protein, your immune system responds, and the protein is cleared. For people who had concerns about mRNA technology specifically, this is the currently approved alternative in the U.S.
Safety and Side Effects
Common side effects of Novavax are similar to other COVID vaccines: soreness at the injection site, fatigue, headache, and muscle pain, typically lasting one to two days. The overall side effect profile has been described as favorable compared to mRNA vaccines in clinical trials, with generally lower rates of systemic reactions like fever.
One serious but rare risk to be aware of: there is a small increased risk of myocarditis and pericarditis (inflammation of the heart or its surrounding lining) following Novavax vaccination. This signal appeared in clinical trial data and in post-authorization safety monitoring outside the United States. The same risk exists with mRNA vaccines. In both cases, the risk is low, and cases have generally been mild and resolved with standard treatment.
Other Non-mRNA Vaccine Types Used Globally
Protein subunit vaccines aren’t the only non-mRNA option that exists. Two other technologies have been used for COVID-19 vaccination around the world, though neither is currently authorized in the United States.
Viral Vector Vaccines
These vaccines, including the Johnson & Johnson and AstraZeneca shots, use a harmless modified virus (typically an adenovirus, the type that causes common colds) as a delivery vehicle. The adenovirus is engineered to carry genetic instructions for the COVID-19 spike protein into your cells. Once inside, your cells read those instructions, build spike proteins, display them on the cell surface, and trigger an immune response. The adenovirus itself cannot replicate or cause illness. While this approach does deliver genetic material to your cells (DNA rather than mRNA), it uses a different mechanism than the Pfizer and Moderna vaccines. The J&J vaccine’s authorization was revoked in the U.S. in 2023 due to the rare risk of a serious blood clotting condition.
Inactivated Virus Vaccines
Vaccines like China’s CoronaVac and Sinopharm use a killed version of the entire SARS-CoV-2 virus. The virus is grown in a lab, then chemically treated so it can no longer replicate or cause infection. When injected, the inactivated virus exposes your immune system to multiple viral proteins at once, not just the spike. This is the oldest vaccine technology in existence, used for decades in flu shots and polio vaccines. These vaccines were never authorized in the U.S. but have been administered to billions of people in Asia, South America, and the Middle East.